Biosimilar Litigation Settlement Score Card: Genentech-Pfizer Herceptin Agreement Is 10th Deal

Genentech inks second settlement of trastuzumab biosimilar litigation; suits ongoing against Amgen, Celltrion/Teva, and Samsung with joint claim construction proceedings.

Courthouse Inscription

Genentech Inc. and Pfizer Inc. entered into a settlement agreement to end litigation over Pfizer's biosimilar to Herceptin (trastuzumab), two months before the user fee goal date for US FDA action on Pfizer's product.

The companies disclosed the agreement in a Dec. 4 filing with the US District Court for the District of...

More from United States

More from North America